United States · Platforms & data · Yahoo Finance

Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule

Published by Yahoo Finance · United States 9 h ago

Johnson & Johnson (NYSE:JNJ) today announced promising Phase 1 results for JNJ-6143 (formerly HLD-0915), an investigational once-daily oral Regulated Induced Proximity Targeting…

Read the full article on Yahoo Finance Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (finance.yahoo.com)

Also worth reading

MarketBeat

Titan Investment Management LLC Makes New $4.43 Million Investment in Eli Lilly and Company $LLY

The Motley Fool

Elon Musk Wants to Give Every American Child a Share of SpaceX. Here's What It Would Cost -- and What It Means for Everyone Else Holding the Stock

MarketWatch

My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?

TheStreet

Gold prices break $4,000 as investors brace for crucial test

Benzinga

Myro (MYRO) Price Prediction: 2025, 2026, 2030

Stocktwits